< Back to news

New human study with FrieslandCampina’s Vivinal GOS powder shows improved intestinal barrier function in obese adults

November 13, 2018

The University of Nebraska in Lincoln (USA), Rush University Medical Center in Chicago (USA) and the University of Alberta in Edmonton (Canada) have recently completed a study into the effects of prebiotics, probiotics and synbiotics on intestinal barrier function and gut microbiota in obese adults. One of the results of the study was that consumption of galacto-oligosaccharides (Vivinal GOS powder) significantly reduces certain markers of gut permeability, indicating an improved intestinal barrier function.1

High gut permeability or ‘leaky gut’ is associated with a higher concentration of harmful compounds in the bloodstream, which can result in inflammation and potentially to the development of disorders such as inflammatory bowel disease, type 2 diabetes and cardiovascular disease.1,2,3 Obese adults are more susceptible to high permeability of the gut than adults who have a normal weight.1,4

Professor Robert Hutkins of the University of Nebraska: As far as we are aware, this is the first study in humans showing that GOS improves intestinal barrier function. This provides a rationale for their use in disorders with an underlying leakiness of the gut.”

In addition, consumption of GOS showed a clear increase in bifidobacteria (one of the major bacteria in the gut), which was also observed in previous human studies.5,6 Bifidobacteria numbers are strongly associated with improvements in intestinal barrier function.1,7 Improving intestinal barrier function also seems relevant in older adults with gastrointestinal symptoms8 and patients.2,9

Erik Torringa, Product Group Manager at FrieslandCampina Ingredients: FrieslandCampina has been market leader in infant nutrition with Vivinal GOS for over a decade. Vivinal GOS is an important ingredient in infant formula. Studies in infants have shown beneficial effects of GOS on among others gut microbiota composition6,10 and defecation.6,11 These new data would point to a much broader use of Vivinal GOS in food and medical applications, over and above infant nutrition.”

  1. Krumbeck, JA. et al. (2018)
  2. Vancamelbeke, M. & Vermeire, S. (2017)
  3. Esser, N. et al. (2014)
  4. Cani, PD. (2016)
  5. Walton, GE. et al. (2012)
  6. Ben, X-M. et al. (2008)
  7. Cani, PD. et al. (2007
  8. Ganda Mall, J-P. et al. (2018)
  9. Salim, SY. & Söderholm, JD. (2011)
  10. Fanaro, S. et al. (2009)
  11. Williams, T. et al. (2014)

This information is intended for industrial customers only; it is not intended for consumers.

Potential consumer benefits are not to be considered as health claims. They should be considered as potential leads that might be developed into health claims complying with the local legal requirements.